Verastem, Inc.
VSTM
Positions held
Your positionsVSTM isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $734.47M | Enterprise value | $682.45M | Trailing P/E | — | Forward P/E | -10.81 |
| PEG | — | Price / book | 8.71 | Beta | 0.39 | Dividend yield | 0.00% |
| Revenue growth | 17.8% | Earnings growth | — | Gross margin | 87.6% | Operating margin | -81.6% |
| Profit margin | -2.3% | ROE | -4.7% | ROA | -49.6% | Debt / equity | 1.69 |
| Current ratio | 2.26 | Free cash flow | -$103.43M | Analyst recommendation | strong_buy | Mean target | $15.00 |
| 52w high | $10.82 | 52w low | $3.43 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $40.1M | $18.7M | $17.5M | $11.2M | $2.1M | — |
| Op margin | -81.6% | -240.5% | -236.5% | -362.2% | -2047.9% | — |
| Net income | -$34.7M | -$36.6M | -$32.9M | -$98.5M | -$25.9M | — |
| Gross margin | 89.9% | 83.7% | 83.5% | 82.6% | 79.1% | — |
| Gross profit | $36.0M | $15.6M | $14.6M | $9.3M | $1.7M | — |
| Operating income | -$32.7M | -$44.9M | -$41.5M | -$40.7M | -$43.8M | — |
- Revenue +115% vs prior quarter ($40M vs $19M).
- Gross margin 89.9% (was 83.7% prior quarter).
- Operating margin expanded to -81.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $30.9M | $10.0M | $0.0M | $2.6M |
| Op margin | -550.3% | -1149.6% | — | -2809.6% |
| Net income | -$209M | -$131M | -$87.4M | -$73.8M |
| Gross margin | 82.9% | 100.0% | — | 100.0% |
| Gross profit | $25.6M | $10.0M | $0.0M | $2.6M |
| Operating income | -$170M | -$115M | -$92.1M | -$72.9M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · B. Riley Adjusts Verastem Price Target to $19 From $16, Maintains Buy Rating
2026-10-06 · Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
2026-10-05 · Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-28 · KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
2026-09-22 · Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
2026-09-18 · Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says
2026-09-17 · Wolfe Research Initiates Verastem at Outperform
2026-09-08 · Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
Price (daily)
Full chart · RSI · MACD · patterns